Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights

A Decade of SG&A Trends in Biotech: Bio-Techne vs. Corcept Therapeutics

In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. Over the past decade, Bio-Techne Corporation and Corcept Therapeutics Incorporated have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Bio-Techne's SG&A expenses surged by over 550%, reflecting its aggressive growth and expansion strategies. In contrast, Corcept Therapeutics exhibited a more moderate increase of approximately 430% during the same period, indicating a steady yet cautious approach.

Bio-Techne's expenses peaked in 2024, while Corcept's data for that year remains unavailable, suggesting potential strategic shifts or reporting delays. This comparison highlights the dynamic nature of financial management within the biotech sector, offering insights into how these companies allocate resources to support their operational and strategic goals. Investors should consider these trends when evaluating potential opportunities in the biotech market.